- Home
- ZVRA
as 10-29-2025 4:00pm EST
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Upcoming Earnings Alert:
Get ready for potential market movements as Zevra Therapeutics Inc. ZVRA prepares to release earnings report on 05 Nov 2025.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | CELEBRATION |
| Market Cap: | 467.6M | IPO Year: | 2015 |
| Target Price: | $22.57 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.19 - $13.16 | Next Earning Date: | 11-05-2025 |
| Revenue: | $62,020,000 | Revenue Growth: | 161.81% |
| Revenue Growth (this year): | 336.43% | Revenue Growth (next year): | 54.26% |
Stock Insider Trading Activity of Zevra Therapeutics Inc. (ZVRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shih Alvin | ZVRA | Director | Sep 12 '25 | Buy | $7.89 | 20,000 | $157,800.00 | 20,000 | |
| FAVORITO TAMARA A | ZVRA | Director | Sep 12 '25 | Buy | $7.79 | 3,175 | $24,718.01 | 3,894 | |
| Bode John B | ZVRA | N/A | Aug 19 '25 | Buy | $9.17 | 5,000 | $45,825.00 | 45,000 |
Latest Zevra Therapeutics Inc. News
ZVRA Breaking Stock News: Dive into ZVRA Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains?
Simply Wall St.
20 days ago
Zevra Therapeutics (ZVRA): Evaluating Valuation Following Insider Buying and Sustained Revenue Growth
GlobeNewswire
23 days ago
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Investor's Business Daily
24 days ago
Zevra Therapeutics Stock Sees Healthy RS Rating Jump To 73
GlobeNewswire
5 months ago
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
Insider Monkey
5 months ago
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT
GlobeNewswire
5 months ago
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees
Simply Wall St.
5 months ago
With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest
Compare ZVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVRA Zevra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.